# Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

> **NCT03945292** · PHASE2 · COMPLETED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 40 (actual)

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** Fazisiran Injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03945292
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-07
- **Primary completion:** 2021-11-08
- **Final completion:** 2023-09-18
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945292, "Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03945292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*